

THE OFFICIAL IOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

- Article Title: Effects of Asenapine in Bipolar I Patients Meeting Proxy Criteria for Moderate-to-Severe Mixed Major Depressive Episodes: A Post Hoc Analysis
- Author(s): Michael Berk, MD, PhD; John Tiller, MD, PhD; Jun Zhao, MD, PhD; Lakshmi N. Yatham, MBBS; Gin S. Malhi, MD; and Emmanuelle Weiller, PsychD
- **DOI Number:** 10.4088/JCP.13m08827

List of Supplementary Material for the article

1. <u>eTable 1</u> Treatment-Emergent Adverse Events in the Treated Population

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2015 Physicians Postgraduate Press, Inc.

Supplementary eTable 1

supplementary to: Effects of Asenapine in Bipolar I Patients Meeting Proxy Criteria for Moderate to Severe Mixed Major Depressive Episodes; a Post Hoc Analysis

Freatment-Emergent Advers	Placebo (n=26)	Asenapine (n=33)	Olanzapine (n=39)
Subjects with ≥ 1 AE, n (%)	17 (65.4)	28 (84.9)	29 (74.4)
Subjects with AE, n (%)			
Sedation	2 (7.7)	5 (15.2)	8 (20.5)
Increased appetite	0	3 (9.1)	2 (5.1)
Rash	1 (3.9)	3 (9.1)	0
Somnolence	1 (3.9)	3 (9.1)	3 (7.7)
Weight increase	0	3 (9.1)	6 (15.4)
Akathisia	0	2 (6.1)	2 (5.1)
Contusion	0	2 (6.1)	0
Depression	0	2 (6.1)	0
Hypoaesthesia oral	0	2 (6.1)	1 (2.6)
Muscle twitching	0	2 (6.1)	0
Pain in extremity	0	2 (6.1)	0
Tremor	0	2 (6.1)	2 (5.1)
Dry mouth	1 (3.9)	1 (3.0)	5 (12.8)
Edema peripheral	0	1 (3.0)	2 (5.1)

^aAdverse events that were reported in \geq 5% of the asenapine or olanzapine groups and were more than twice that in the placebo group.